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Cognitive functioning 
following stabilisation from first episode mania
Rothanthi Daglas1,2, Kelly Allott1,2, Murat Yücel3, Lisa P. Henry1, Craig A. Macneil4, Melissa K. Hasty4, 
Michael Berk1,2,5,6,7 and Sue M. Cotton1,2*
Abstract 
Background: The purpose of this study was to examine cognitive functioning in people following first-episode 
mania relative to a demographically similar healthy control group.
Methods: Forty-one patients, who had recently stabilised from a first manic episode, and twenty-one healthy con-
trols, were compared in an extensive cognitive assessment.
Results: First-episode mania participants had significantly lower Full-Scale IQ (FSIQ) relative to healthy controls; 
however, this finding could be driven by premorbid differences in intellectual functioning. There were no significant 
differences between groups in Verbal IQ (VIQ) and Performance IQ (PIQ). First-episode mania participants performed 
significantly poorer than healthy controls in processing speed, verbal learning and memory, working memory, and 
cognitive flexibility with medium-to-large effects. There were no group differences in other measures of cognition.
Conclusions: Participants following first-episode mania have poorer global intelligence than healthy controls, and 
have cognitive difficulties in some, but not all areas of cognitive functioning. This highlights the importance of early 
intervention and cognitive assessment in the early course of the disorder.
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Background
Cognitive impairments during euthymia in people in all 
stages of bipolar disorder have been reported by several 
meta-analyses, with findings of medium to large effect in 
processing speed, verbal learning and memory, non-ver-
bal memory, working memory, verbal fluency, sustained 
attention and executive functions (Arts et al. 2008; Bora 
et al. 2009; Bourne et al. 2013; Mann-Wrobel et al. 2011). 
There has been limited research conducted on cognitive 
functioning during the early stages of the illness, thus the 
timing and onset of cognitive change remains unclear.
Recently, two meta-analyses on adults with first epi-
sode bipolar disorder (including any polarity of illness) 
have identified impairments in most cognitive domains 
relative to healthy control (HC) participants (Bora 
and Pantelis 2015; Lee et  al. 2014). However, a recent 
systematic review on first episode mania (FEM) that 
included adolescents as well as adult samples, revealed 
discrepancies between study findings across most cogni-
tive domains, apart from a consistently reported deficit in 
working memory during remission, and that verbal flu-
ency and non-verbal memory remained intact (Daglas 
et al. 2015). The literature regarding intelligence in FEM 
has revealed that patients perform worse than HCs in 
global IQ (Elshahawi et  al. 2011; López-Jaramillo et  al. 
2010), and on measures of non-verbal intelligence (Hell-
vin et  al. 2012; Torres et  al. 2010); however, the stud-
ies in FEM (included in the systematic review) had not 
controlled for the differences observed between FEM 
and HC groups in IQ, which may have contributed to 
the inconsistencies between study findings (Daglas et al. 
2015). This is in contrast to a meta-analysis that reported 
preserved current IQ in people with established bipolar 
disorder (Bora et  al. 2009). Moreover, there appears to 
be a bi-modal pattern regarding school performance in 
asymptomatic adolescents (aged 15–16  years) who later 
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develop bipolar disorder. Those with the highest school 
grades displayed a nearly fourfold increased risk of devel-
oping the disorder by age 31, whilst those with the lowest 
school performance were found to have close to a twofold 
increased risk (MacCabe et al. 2010). Predictors of lower 
intellectual functioning in individuals with bipolar dis-
order include an earlier age of onset, greater number of 
prior episodes and hospitalisations (Denicoff et al. 1999).
Although cognitive deficits have been identified during 
remission in bipolar disorder, the effects of intelligence, 
residual symptoms, medication use, number of hospitali-
sations and number of past episodes may impact upon 
the findings (Bourne et  al. 2013; Donaldson et  al. 2003; 
Nehra et  al. 2006; Thompson et  al. 2005; Torres et  al. 
2010). The first diagnostic episode for bipolar I disorder 
enables the assessment of cognitive functioning prior to 
the effects of covariates such as prolonged medication 
use and recurrent manic episodes. Most of the studies 
conducted to date have included adult samples with FEM 
(Daglas et al. 2015) and have not considered that the inci-
dence of FEM is greatest between 16 and 30 years (Ken-
nedy et  al. 2005), and that there may be developmental 
differences in cognition between younger and older 
populations.
Thus, the aim of the current study was to examine 
cognitive functioning of young people (15–25 years) fol-
lowing FEM relative to a demographically similar HC 
group. The cognitive domains considered were process-
ing speed, attention, sustained attention, verbal learning 
and memory, non-verbal learning and memory, working 
memory, verbal fluency and executive functions. Due to 
diagnostic instability in the early phases of the illness, 
and that an accurate diagnosis is on average delayed for 
7.5  years in people with bipolar disorder, any presenta-
tion of FEM will be considered in this study (Ghaemi 
et  al. 1999; Schimmelmann et  al. 2005). It was hypoth-
esised that FEM participants would perform significantly 
worse than HCs in processing speed, attention, sustained 
attention, verbal learning and memory, working mem-
ory and executive functions; and that the groups would 
not significantly differ in verbal fluency and non-verbal 
memory. Furthermore, FEM participants were expected 
to perform more poorly than HCs in full-scale IQ (FSIQ) 
and performance IQ (PIQ), but that the groups would 
have similar verbal IQ (VIQ).
Methods
Design
This study involved secondary analysis of baseline 
data from a single-blinded Randomised Control Trial 
(RCT) conducted at Orygen, The National Centre of 
Excellence in Youth Mental Health, Melbourne, Aus-
tralia. The focus of the trial was on the effectiveness of 
quetiapine fumarate compared to lithium carbonate 
monotherapy for the maintenance treatment of FEM 
over a 12-month period. This trial was registered with 
the Australian and New Zealand Clinical Trials Registry 
ACTRN12607000639426. Neuropsychological data were 
also collected on a separate HC group that was not part 
of the RCT, using the same time-points and measures.
Sample and setting
The FEM patients were recruited between 2006 and 2013 
from outpatient clinics of OYH and Monash Health, 
located within the Western, North Western and South 
Eastern suburbs of Melbourne, respectively. To satisfy 
inclusion criteria for the RCT, the FEM patients were 
required to have: (1) clinically stabilised from a first 
treated manic episode on a combination of quetiapine 
and lithium for a least 1  month prior to randomisation 
(stabilisation of mental state was based on clinical judg-
ment by the treating clinicians on the basis of a global 
clinical assessment); (2) met Diagnostic and Statisti-
cal Manual of Mental Disorders-Fourth Edition-Text 
Revision (DSM-IV-TR; APA, 2000) criteria for bipolar I 
disorder, schizoaffective disorder-bipolar type, or a sub-
stance-induced mood disorder; (3) scored a minimum of 
20 on the Young Mania Rating Scale (YMRS) during the 
first manic episode; and (4) been aged 15–25 years at the 
time of recruitment.
FEM patients were excluded if they had a clinically 
relevant systemic medical disorder, biochemical or hae-
matological abnormalities or unstable diabetes mellitus, 
were pregnant or lactating, had a sensitivity or allergy to 
components of lithium or quetiapine, were non-fluent in 
English, had a history of epilepsy, were at immediate risk 
of harm to self or others, or had an organic mental dis-
ease including intellectual disability (FSIQ < 70). The use 
of potent cytochrome P450 inhibitors and inducers was 
also prohibited during the study.
HCs were matched as closely as possible to the FEM 
group in age, sex and premorbid intelligence, and were 
recruited from similar regions of Melbourne through 
advertisements in a freely distributed newspaper at 
inner-city metro stations of Melbourne, the Orygen web-
site, and by word of mouth. Due to recruitment feasibil-
ity, FEM and HC participants were recruited at a ratio of 
2:1. Individuals interested in participating contacted the 
researchers and were given a detailed description of the 
study. Prior to providing informed consent, the HCs were 
assessed for current or past mental health disorders with 
the screening tool of the Structured Clinical Interview 
(Patient Edition) for DSM-IV-TR. HCs were excluded if 
they had a history of, or current mental health disorder, 
substance abuse or dependence, an FSIQ  <  70, or were 
not 15–25 years of age.
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Measures
Neuropsychological measures
One assessor (RD) was trained in standardised neuropsy-
chological testing and clinical assessment of this clinical 
population and conducted all assessment components of 
the study. The neuropsychological battery was adminis-
tered in the same order for all participants and consisted 
of psychometrically robust, valid and standardised tests. 
Cognitive functions that were assessed included intelli-
gence, processing speed, attention span, sustained atten-
tion, verbal learning and memory, non-verbal learning 
and memory, working memory, verbal fluency and execu-
tive functions.
Intelligence
To measure estimated premorbid intelligence, the 
Wechsler Test of Adult Reading (WTAR) was used (The 
Psychological Corporation 2001). As a measure of cur-
rent intelligence, the Wechsler Abbreviated Scale of 
Intelligence (WASI) was utilised (The Psychological 
Corporation 1999). From the WASI, FSIQ, VIQ and PIQ 
scores were derived.
Processing speed
Four tests of processing speed were administered, includ-
ing Trail Making Test—part A (TMT-A) (Reitan 1955), 
WAIS-III Digit Symbol Coding (Wechsler 1997), the com-
puterised Go/No-Go test to assess the reaction time for 
go responses (see Takagi et al. 2011), and the  CogstateTM 
Detection task (see Hammers et al. 2011, 2012).
Attention
Attention span was assessed with WAIS-III Digit Span-
forward (Wechsler 1997). The computerised Stroop task 
for congruent responses, Go/No-Go test for missed go 
responses (see Takagi et al. 2011), and  CogstateTM Iden-
tification task were used as measures of focused attention 
(see Hammers et al. 2011, 2012).
Sustained attention
A shorter version of the original Attention Network Test 
(ANT) was used to measure sustained attention (Fan 
et al. 2005).
Verbal learning and memory
The Rey auditory verbal learning test (RAVLT) was 
administered to test verbal learning and memory (Lezak 
1983; Rey 1958). The correct recall of words in trial 1 was 
used as a test of immediate memory, and the total cor-
rect recall of the same list of words in five consecutive 
trials was used to measure verbal learning. Delayed ver-
bal recall was measured by the recall of the same list of 
words after a 20-min interval.
Non‑verbal learning and memory
The computerised  CogstateTM One-card leaning 
task (OCL) (see Hammers et  al. 2011, 2012) and the 
 CogstateTM Groton Maze Learning Test (GMLT)—
delayed recall were used as measures of non-verbal learn-
ing and memory (see Snyder et al. 2005).
Working memory
The WAIS-III Digit Span-backward was used to measure 
working memory capacity (Wechsler 1997).
Verbal fluency
The Controlled Oral Word Association Test was used to 
measure semantic (animal category) and phonemic (FAS) 
verbal fluency (see Mitrushina et al. 2005).
Executive functioning
The Trail Making Test—part B (TMT-B) was utilised to 
measure cognitive flexibility (Reitan 1955). To assess 
inhibitory control, computerised versions of the Stroop 
and Go/No-Go tasks were used (see Takagi et al. 2011). 
The  CogstateTM GMLT was used as a test of spatial prob-
lem solving (see Snyder et al. 2005).
Clinical measures
The clinical scales used to assess psychiatric symptoma-
tology included: the YMRS (Young et al. 1978); the Mont-
gomery–Åsberg Depression Rating Scale (MADRS) 
(Montgomery and Asberg 1979); the Brief Psychiatric 
Rating Scale (BPRS), total scores and positive psychotic 
scores (including the 4 subscales: unusual thought con-
tent, hallucinations, suspiciousness and conceptual disor-
ganisation) (Overall and Gorham 1962); and the Clinical 
Global Impression scale—modified for bipolar disorder 
(CGI-BP) (Spearing et al. 1997).
Procedure
The trial adhered to Good Clinical Practice guidelines, 
and was approved by the Human Research Ethics Com-
mittees of Melbourne Health (HREC 2006.644) and 
Monash Health (06138B). All participants or legal guard-
ians (on behalf of participants under 18 years of age) pro-
vided voluntary informed consent. Patients who were 
treated with a combination of quetiapine and lithium for 
their first acute episode of mania were referred to the 
study by the treating psychiatrist or case manager. Once 
patients had clinically stabilised and were transferred to 
outpatient care, they were provided with a full descrip-
tion of the study. Cognitive and clinical assessments 
occurred once the patients had stabilised and had com-
menced monotherapy. The clinical assessment was con-
ducted on the same day as the cognitive assessment for 
most FEM participants (41%). Thirty-one percent of the 
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FEM participants had the clinical assessment within the 
first week, 15% within the 2-weeks and 13% over 2-weeks 
of cognitive testing. The time-point for the structured 
clinical interview for DSM-IV-TR was within 2–4 weeks 
of the cognitive testing.
Data analysis
All statistical analyses were conducted using  IBM®  SPSS® 
Statistics Version 22.0. Descriptive statistics were calcu-
lated for demographic variables, and illness character-
istics. Independent samples t test and Chi-square (χ2) 
analyses were performed to assess for between-group 
differences on demographic variables. Several outliers 
were identified by box plots, and skewness and kurtosis 
values revealed that the cognitive data were differentially 
distributed within the two groups. Therefore, non-para-
metric Mann–Whitney U tests were utilised to compare 
groups for each cognitive measure. To control for the 
effects of multiple comparisons, family-wise error adjust-
ments were made per cognitive domain (α  =  .05/num-
ber of cognitive measures per domain). To determine 
absolute values for effect size (r), z scores were divided 
by the square root of N (r  = Z/√N), as used for non-
parametric tests (Fritz et al. 2012). According to Cohen’s 
(1998) guidelines for r, a small effect size is 0.1, medium 
effect size is 0.3 and a large effect size is 0.5 (Coolican 
2009). The relationship between clinical symptom rating 
(YMRS, MADRS, BPRS and BPRS—positive psychotic 
scores) and cognitive functioning was assessed using 
Pearson’s correlation on any measure that showed a sig-
nificant difference between FEM participants and HCs 
following family-wise adjustment.
Results
The cohort included sixty-one patients who had recently 
stabilised from their first treated manic episode. Of the 
61 FEM patients, 7 were excluded due to not adhering to 
the randomised medication allocation, 2 were deemed 
too unwell to participate by their treating psychiatrist, 
5 relapsed prior to the first assessment, and 6 withdrew 
consent or disengaged from the service. In total, 41 FEM 
participants and 21 HCs were included in the study.
Sample characteristics
Demographic and illness characteristics are presented in 
Table 1. The FEM and HC groups did not differ signifi-
cantly in age, sex and premorbid intelligence. However, 
the difference observed between groups in premorbid 
Table 1 Participant demographics and illness characteristics
FEM first episode mania, HC healthy controls, WTAR Wechsler Test of Adult Reading, YMRS Young Mania Rating Scale, MADRS Montgomery–Åsberg Depression Rating 
Scale, BPRS Brief Psychiatric Rating Scale, CGI-BP Clinical Global Impression scale for bipolar illness, t test independent samples t test, χ2 Chi-square test
a Missing data (FEM, n = 1; HC, n = 1)
b Diagnosis of bipolar I disorder confirmed by treating clinician (n = 1)
c Continuity correction
Demographics variables FEM (n = 41) HC (n = 21) Statistics p value
Age, M (SD) 21.32 (2.26) 21.14 (2.54) t test 0.784
Sex, male, n (%) 32 (78) 11 (52.38) χ2 c 0.074
Premorbid  intelligencea
 Based on WTAR UK norms, M (SD) 94.9 (13.81) 101.70 (9.65) t test 0.054
Education level
 Less than 12 years, n (%) 16 (39) 2 (7) χ2 0.032
 12 years, n (%) 7 (17) 3 (14)
 More than 12 years, n (%) 18 (44) 16 (76)
Diagnosis
 Bipolar I  disorderb, n (%) 35 (85)
 Substance-induced mood disorder, n (%) 4 (10)
 Schizoaffective disorder- bipolar type, n (%) 2 (5)
Symptom rating
 YMRS, total, M (SD) 2.51 (3.57)
 MADRS, total, M (SD) 7.39 (8.95)
 BPRS, total, M (SD) 33.24 (9.32)
 BPRS, positive psychotic subscale, M (SD) 4.63 (1.64)
 CGI-BP, mania severity, M (SD) 1.15 (.573)
 CGI-BP, depression severity, M (SD) 2.05 (1.563)
 CGI-BP, overall severity, M (SD) 2.02 (1.491)
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intelligence was of moderate effect (d = 0.57). On average 
the HC group had spent more years in education than 
the FEM group. The largest percentage of FEM patients 
had a diagnosis of bipolar I disorder (85%), 10% had a 
substance-induced mood episode and 5% were diagnosed 
with schizoaffective disorder-bipolar type. All FEM par-
ticipants had experienced a manic or mixed episode with 
psychotic features.
On average the FEM participants were in remission 
from acute mania (YMRS, M = 2.51, SD = 3.57), did not 
have positive psychotic symptomatology in the BPRS 
(M = 4.63, SD = 1.64), and were rated normal/not ill in 
mania severity on the CGI-BP (M =  1.15, SD =  0.573). 
However, the FEM participants were on average mildly 
depressed (MADRS, M  =  7.39, SD  =  8.95), as also 
identified in the BPRS total psychopathology rating 
(M  =  33.24, SD  =  9.32). FEM participants were con-
sidered minimally ill in depression severity (M  =  2.05, 
SD = 1.56), and in overall bipolar disorder severity on the 
CGI-BP (M = 2.02, SD = 1.49).
Cognitive functioning
The median and minimum/maximum scores for each 
group per cognitive measure and the associated test sta-
tistics and effect sizes are presented in Table 2.
Intelligence
FEM participants had significantly lower FSIQ (p = .014) 
and PIQ (p  =  .046) than HCs, with medium (r  =  .31) 
and small to medium effect (r = .26), respectively. How-
ever, PIQ did not remain significant after family-wise 
adjustment (i.e. α/3). There was no significant difference 
between groups in VIQ (p = .084).
Processing speed
A highly significant group difference was observed 
between groups on the TMT-A (p < .001) and digit sym-
bol coding (p = .002), even after family-wise adjustment 
(i.e. α/4). FEM patients performed substantially slower 
than HCs with a large (r  =  .57) and medium (r  =  .40) 
effect size, respectively.
There were no significant differences between groups 
in ‘go’ reaction time (p =  .480) or  CogstateTM Detection 
time (p = .668).
Attention
The groups did not differ significantly on Digit Span-for-
ward (p =  .532), missed go responses (p =  .753), Stroop 
congruent total errors (p = .928) or in  CogstateTM Identi-
fication time (p = .487).
Sustained attention
FEM and HC groups performed similarly in ANT alert-
ing (p = .785), orienting (p = .677) and executive control 
(p =  .081). There was no significant difference between 
groups in total errors for the no cue (p = .593), spatial cue 
(p =  .351), double cue (p =  .850), congruent (p =  .248) 
and incongruent (p = .432) conditions.
Verbal learning and memory
FEM patients recalled significantly fewer words in trial 
1 of the RAVLT relative to HCs (p =  .002), of medium 
effect (r = .39). FEM patients recalled significantly fewer 
words than HCs in trials 1–5 (p  <  .001) and in delayed 
verbal recall (p < .001), which were both of a medium to 
large effect size (r = .47). These differences remained sig-
nificant after family-wise adjustment (i.e. α/3).
Non‑verbal learning and memory
There were no significant group differences in the OCL 
task (p = .609) or in the GMLT-delayed recall (p = .187).
Working memory
FEM patients had poorer working memory capacity than 
HCs, with a highly significant difference between groups 
in Digit Span-backward (p = .001) with medium to large 
effect (r = .44).
Verbal fluency
There was no significant difference between groups in 
phonemic fluency (p = .122). FEM participants produced 
significantly fewer words than HCs in semantic fluency 
(p = .045), though, this difference did not remain signifi-
cant after family-wise adjustment (i.e. α/2).
Executive functions
A large difference was observed in cognitive flex-
ibility with FEM patients performing worse than HCs in 
TMT-B (p = .004), even after family-wise adjustment (i.e. 
α/5), with a medium effect size (r = .37).
Groups did not differ significantly with respect to 
response inhibition in Go/No-Go false alarm responses 
(p = .063), in Stroop incongruent total errors (p = .974), 
or in Stroop effect (p = .794). Additionally, no significant 
group differences were observed in spatial problem solv-
ing as assessed by GMLT (p = .502).
Relationship between clinical symptomatology 
and cognition
A significant negative correlation was found between rat-
ing scores on the YMRS and the RAVLT trial 1 (p = .033) 
with a moderate effect size (r  =  −  .333). There also 
was a significant negative relationship between symp-
tom rating on the YMRS and scores on the RAVLT 
Page 6 of 11Daglas et al. Int J Bipolar Disord  (2017) 5:39 
Table 2 Cognitive functioning in participants following FEM relative to healthy controls
FEM HC Test statistic Value df p value Effect size
Median (min–max) Median (min–max)
Intelligence (WASI)a
 Verbal IQ 102 (63–128) 109 (96–130) M–W 297.5 61 .084 0.22
 Performance IQ 104 (75–128) 115 (90–129) M–W 280 61 .046 0.26
 Full-scale IQ 107 (70–128) 113 (98–126) M–W 250.5 61 .014 0.31
Processing speed
 Trail Making Test-Aa 31 (19–72) 22 (13–41) M–W 120.5 61 < .001 0.57
 Digit symbol  codinga 73 (30–106) 80 (60–125) M–W 207 61 .002 0.4
 Go/No-Gob, go reaction time 294.96 (238.13–424.11) 304.91 (258.77–387.96) M–W 355 60 .480 0.09
 Cogstatec, detection reaction time 2.44 (2.32–2.69) 2.43 (2.36–2.59) M–W 362 58 .668 0.06
Attention
 Digit Span  forwarda 8 (4–12) 10 (5–12) M–W 370 61 .532 0.08
 Go/No-Gob, go misses 0 (0–8) 0 (0–6) M–W 382 60 .753 0.04
 Stroopd, congruent errors 2.5 (0–15) 2 (0–13) M–W 374.5 58 .928 0.01
 Cogstatec, identification reaction time 2.66 (2.55–2.91) 2.66 (2.54–2.80) M–W 345.5 58 .487 0.09
Sustained  attentione
 ANT, alerting reaction time 44.61 (− 99.46 to 162.3) 38.56 (− 21.45 to 97.28) M–W 373 59 .785 0.04
 ANT, orienting reaction time 164.15 (13.67–316.42) 159.54 (15.70–232.76) M–W 364 59 .677 0.05
 ANT, executive control reaction time 226.74 (6.37–794.91) 189.81 (84.25–273.07) M–W 281 59 .081 0.23
 ANT, no cue errors 1 (0–5) 1 (0–3) M–W 358 59 .593 0.07
 ANT, spatial cue errors 1 (0–5) 1 (0–2) M–W 335.5 59 .351 0.12
 ANT, double cue errors 1 (0–5) 1 (0–10) M–W 378.5 59 .850 0.02
 ANT, congruent errors 0 (0–2) 0 (0–3) M–W 329.5 59 .248 0.15
 ANT, incongruent errors 3 (0–9) 2.5 (0–13) M–W 341.5 59 .432 0.1
Verbal learning and  memorya
 Rey auditory verbal learning  teste—trial 1 6 (3–12) 7.5 (4–12) M–W 215 61 .002 0.39
 Rey auditory verbal learning  teste—trials 1–5 52 (26–66) 59.50 (42–71) M–W 170.5 61 < .001 0.47
 Rey auditory verbal learning  teste—delayed 
recall
11 (3–15) 14 (10–15) M–W 174 61 < .001 0.47
Non-verbal learning and memory
 Cogstate, one-card  learningf 1.01 (0.26–1.22) 1.03 (0.82–1.12) M–W 339.5 57 .609 0.07
 Cogstate, Groton Maze Learning Test, delayed, 
 errorsg
6 (0–24) 4 (0–11) M–W 291.5 57 .187 0.17
Working memory
 Digit Span  backwarda 4 (1–10) 7 (3–12) M–W 186.5 61 .001 0.44
Verbal  fluencya
 FAS 37 (17–59) 43 (17–58) M–W 309.5 61 .122 0.2
 Animal category 21 (11–32) 23 (16–27) M–W 280 61 .045 0.26
Executive functions
 Trail Making Test-Bh 75 (31–215) 51 (30–116) M–W 207 60 .004 0.37
 Go/No-Gob, no-go false alarms 9.5 (2–21) 6.5 (1–16) M–W 282 60 .063 0.24
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trials 1–5 (p = .029), which was of a moderate effect size 
(r = − .342). Furthermore, a significant negative correla-
tion was found between general psychopathology rating 
(BPRS total) and the RAVLT trials 1–5 (p = .008), which 
was of a moderate to large effect size (r = − .408). There 
were no other significant correlations found between 
clinical symptom rating scales and cognition.
Discussion
The purpose of this study was to investigate cognitive 
functioning in youth following FEM. FEM patients were 
found to have lower FSIQ than HCs. While the groups 
were statistically matched in estimated premorbid intel-
ligence, the difference in premorbid IQ was of medium 
effect and so the difference in current FSIQ may be driven 
by true pre-existing group differences or the inherent dif-
ficulties encountered matching FEM and HC on premor-
bid intelligence. Furthermore, FEM patients were still 
within the average intelligence range when compared to 
norms of people from a similar age group. Furthermore, 
the groups did not significantly differ in verbal and per-
formance IQ after controlling for multiple comparisons. 
Previous research has been mixed showing that patients 
following FEM had poorer global intellectual functioning 
compared to HCs (Elshahawi et al. 2011; López-Jaramillo 
et al. 2010) and that FEM patients and HCs did not dif-
fer in verbal IQ, though FEM patients performed more 
poorly than HCs in subtests of performance IQ, including 
Block Design (Hellvin et  al. 2012) and spatial reasoning 
(Hellvin et al. 2012; Torres et al. 2010).
Our findings indicate that FEM patients displayed cog-
nitive impairments in some, but not all areas of cognitive 
functioning. First, as expected FEM patients performed 
worse than HCs in tests of processing speed, verbal 
learning and memory, working memory and cognitive 
flexibility. Second, phonemic verbal fluency and non-
verbal learning and memory were not impaired relative 
to HCs; and differences observed in sematic verbal flu-
ency were no longer apparent after family-wise adjust-
ment. Contrary to our hypothesis, there were no group 
differences found in attention span, sustained attention 
or in the computerised tests of psychomotor speed and 
response inhibition. Although findings in the literature 
examining cognitive functioning in the early stages of 
Table 2 continued
FEM HC Test statistic Value df p value Effect size
Median (min–max) Median (min–max)
 Stroop  effectd, reaction time 360.02 (97.20–603.79) 380.58 (115.75–618.27) M–W 364 58 .794 0.03
 Stroopd, incongruent errors 7 (1–26) 6 (3–24) M–W 378 58 .974 < 0.01
 Cogstatec, Groton Maze Learning Test, errors 54 (23.00–142.00) 51.00 (32.00–115.00) M–W 347 58 .502 0.09
FEM first episode mania, HC healthy controls, ANT attention network test, M–W Mann–Whitney U test
ANT, alerting reaction time = no cue reaction time − double cue reaction time
ANT, orienting reaction time = double cue reaction time − spatial cue reaction time
ANT, executive control reaction time = incongruent trials reaction time − congruent trials reaction time
ANT, no cue errors = total errors for the no cue conditions
ANT, spatial cue errors = total errors for the spatial cue conditions
ANT, double cue errors = total errors for the double cue conditions
ANT, congruent errors = total errors for the congruent trials
ANT, incongruent errors = total errors for the incongruent trials
Stroop effect = incongruent condition reaction time − congruent condition reaction time
Stroop, congruent errors = total errors for the congruent trials
Stroop, incongruent errors = total errors for the incongruent trials
Go/No-Go, go reaction time = reaction time for go responses
Go/No-Go, no-go false alarms = sum of false responses to no-go stimulus
Go/No-Go, go misses = sum of missed responses to go stimulus
a Missing data (HC, n = 1)
b Missing data (FEM, n = 1; HC, n = 1)
c Missing data (FEM, n = 5)
d Missing data (FEM, n = 3; HC, n = 1)
e Missing data (FEM, n = 2; HC, n = 1)
f Missing data (FEM, n = 4; HC, n = 1)
g Missing data (FEM, n = 5; HC, n = 1)
h Missing data (HC, n = 2)
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bipolar disorder is somewhat mixed (Daglas et al. 2015), 
the results from the current study are generally compara-
ble to the majority of research findings in FEM.
Regarding processing speed, Elshahawi et al. (2011) also 
revealed impairments in FEM patients relative to HCs as 
assessed by TMT-A and Digit Symbol Coding. Addition-
ally, Hellvin et  al. (2012) found that FEM patients per-
formed worse than HCs in Digit Symbol Coding, whilst 
reporting no difference between groups in Stroop perfor-
mance. On the other hand, Torres et al. (2010) found that 
FEM patients and HCs performed alike in both Stroop 
and in TMT-A. Another study by López-Jaramillo et al. 
(2010) reported a similar performance between FEM 
patients and HCs in TMT-A and in Digit Symbol Cod-
ing; however, this study had recruited relatives of the 
FEM patients as HCs, which may have influenced their 
findings. It has been reported that first-degree relatives 
of people with bipolar I disorder have a slower ability to 
process information than those without a family history 
of psychiatric illnesses (Antila et al. 2007).
Deficits in working memory have been reported by 
most first episode studies across the bipolar disorder 
spectrum relative to HCs (Barrett et al. 2009; Elshahawi 
et  al. 2011; Hellvin et  al. 2012; Hill et  al. 2009; López-
Jaramillo et al. 2010). However, two studies that assessed 
working memory using the letter–number sequencing 
(LNS) task failed to find a significant difference between 
groups (Torres et al. 2010; Zanelli et al. 2010). An expla-
nation for this may be that FEM patients may have a 
weaker activation of the phonological loop required for 
verbal memory encoding (as in the Digit Span task), but 
may have maintained the ability to process more complex 
information, such as the interaction required between 
visuospatial functions, processing speed, and working 
memory when switching between letters and numbers in 
LNS (Crowe 2000; Haut et al. 2000).
Our study revealed that FEM patients had deficits 
in verbal learning and memory, but spared non-verbal 
learning and memory. Notably, when either mania or 
general psychopathology symptoms increased, verbal 
learning and memory performance decreased. Similar to 
our findings, Torres et  al. (2010) reported that patients 
who had recently experienced a first episode of mania 
recalled significantly fewer words than HCs. Whilst, 
another study failed to find a significant difference 
between groups in total words recalled (trials 1–5), there 
were a significantly higher percentage of FEM patients 
(24%) who had clinically impaired verbal learning on the 
task (1.5 standard deviations below the mean of the HC 
group) than HCs (5%) (Hellvin et al. 2012). Impairments 
in delayed verbal recall have also been reported by previ-
ous studies in people with bipolar disorder experiencing 
their first episode of mania or psychosis (Hellvin et  al. 
2012; Zanelli et al. 2010).
Most research on first episode patients across the 
bipolar spectrum has revealed that non-verbal learning 
and memory remains intact (Hellvin et  al. 2012; López-
Jaramillo et  al. 2010; Torres et  al. 2010; Zanelli et  al. 
2010). Only one study of patients with bipolar disorder 
in remission from their first episode of psychosis identi-
fied a deficit in non-verbal memory (Barrett et al. 2009). 
Furthermore, a study on individuals at ultra-high risk for 
psychosis identified impaired visual reproduction relative 
to HCs, in patients who later developed a first episode 
of psychosis (Brewer et al. 2005). A deficit in non-verbal 
memory has also been identified in patients with recur-
rent bipolar disorder (Arts et  al. 2008). Thus, dysfunc-
tion in non-verbal memory may reflect a deficit primarily 
related to psychosis or more chronic forms of bipolar dis-
order that appears to remain unaffected following FEM.
Our finding that attention was not impaired is consist-
ent with the majority of first episode studies in bipolar 
disorder (Hellvin et al. 2012; Hill et al. 2009; López-Jara-
millo et al. 2010; Torres et al. 2010). Although one study 
identified impairment in attention span in FEM patients 
relative to HCs, this study was limited by their recruit-
ment of hospital employees from the same hospital as the 
FEM patients for the HC group, and therefore may not 
have been truly representative of the general population 
(Elshahawi et al. 2011).
Furthermore, our finding of no deficit in sustained 
attention is contrary to a previous study by Torres et al. 
(2010), who found that FEM patients performed signifi-
cantly worse in this domain than HCs. The inconsistency 
between these study findings may be largely attributed 
to the different tests that were administered. The sus-
tained attention task used in the current study required 
the unique activation of alerting, orienting and executive 
control pathways, which is a variation from more com-
monly used tests of sustained attention such as the rapid 
visual information processing task. However, as there has 
only been one previous study that has assessed sustained 
attention in FEM, further studies are required in respect 
to this domain.
In accordance with the recent systematic review on 
FEM (Daglas et  al. 2015), both phonemic and semantic 
verbal fluency remained intact in the current study of 
FEM patients. Whilst a recent meta-analysis in the first 
episode bipolar disorder identified deficits in verbal flu-
ency, these were of small effect and were observed in 
only two studies (Lee et al. 2014). However, these studies 
had compared adult FEM patients to a poorly matched 
HC group in age, sex and/or education level (Nehra et al. 
2006; Zanelli et al. 2010).
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Furthermore, we identified that there were no impair-
ments in most domains of executive function, except 
for cognitive flexibility. Cognitive inflexibility has been 
reported in the acute state of FEM (Fleck et  al. 2008). 
Most studies on patients following FEM have reported 
that cognitive flexibility remained intact relative to HCs 
(Hellvin et  al. 2012; López-Jaramillo et  al. 2010; Tor-
res et  al. 2010), with the exception of Elshahawi et  al. 
(2011) who identified deficits in cognitive flexibility dur-
ing remission in patients who had FEM with psychotic 
features relative to HCs. Most studies in FEM dur-
ing the acute state (Lebowitz et  al. 2001) and in remis-
sion (López-Jaramillo et al. 2010; Torres et al. 2010) are 
in support of our finding that response inhibition is not 
impaired following FEM. The deficits in response inhibi-
tion identified by one study of FEM patients who were 
predominantly depressed at the time of testing may have 
been reflective of the ongoing mood symptoms (Hellvin 
et al. 2012). A study by Malhi et al. (2007) identified that 
depressed patients with bipolar disorder had significantly 
poorer response inhibition than HCs, a finding that 
was not observed for either the euthymic or hypomanic 
groups.
The decline in cognitive functioning with illness pro-
gression has been elucidated by studies comparing FEM 
patients to those with multiple episodes (Elshahawi et al. 
2011; Hellvin et  al. 2012; López-Jaramillo et  al. 2010; 
Torres et  al. 2010). Relative to findings of widespread 
cognitive impairments in people with chronic forms of 
bipolar disorder, our findings suggest that specific deficits 
in processing speed, verbal learning and memory, work-
ing memory and cognitive flexibility might occur from 
the early stages of the illness. It may be postulated that 
the impairments reported in attention, sustained atten-
tion, non-verbal memory, verbal fluency and other exec-
utive functions may result from recurrent episodes (Bora 
et al. 2009; Bourne et al. 2013; Mann-Wrobel et al. 2011; 
Torres et al. 2007), as reported deficits in these domains 
are largely inconsistent in studies in FEM (Daglas et  al. 
2015). Neuroimaging studies have provided evidence in 
support of neuroprogression in bipolar disorder, with 
findings of prefrontal, cerebellum volume and ventricu-
lar abnormalities seen in patients with recurrent epi-
sodes relative to first episode patients or HCs (DelBello 
et al. 1999; Mills et al. 2005; Strakowski et al. 2002). Some 
structural brain abnormalities pertaining to the subgen-
ual prefrontal cortex, have also been identified early in 
the course of the illness, which may reflect the cognitive 
deficits in the specific domains observed by studies in 
FEM (Strakowski et al. 2005).
Amongst the strengths of this study is the rela-
tively large sample size of a specified group of psychi-
atric patients recruited from a naturalistic treatment 
environment. Given the sample size, post hoc power 
analyses indicated that we had sufficient power at .80 to 
detect moderate to large effects when α was set at .05. 
Additionally, in this study we administered an exten-
sive cognitive battery, which covered several cognitive 
domains and included computerised cognitive testing to 
increase sensitivity in identifying deficits. Importantly, 
the FEM participants were matched as closely as possi-
ble to the HC group in age and sex. We also attempted 
to match the groups as closely as possible on premor-
bid intelligence; however, the FEM group had an aver-
age premorbid intelligence score 6.8 lower than the HC. 
Although the between-group difference in premorbid 
intelligence was not statistically significant, it was of 
moderate effect and might have explained the differences 
between groups in specific cognitive domains. It was not 
possible to control for premorbid intelligence and other 
factors (e.g. education) in non-parametric analyses. How-
ever, it is argued, that clinically such a difference is not 
necessarily meaningful and both groups had mean pre-
morbid intelligence scores that would be considered in 
the average or normal range. Also highlighted are the dif-
ficulties matching patient and healthy control groups on 
such variables.
Other limitations included that stabilisation from acute 
mania was based on clinical judgment without use of an 
objective mania cut-off score, and on average the FEM 
participants were mildly depressed. Medication effects 
may have influenced cognitive functioning; it would 
be methodologically ideal but ethically questionable to 
include a medication-naive group. Although this study 
utilised a catchment area service, the generalisability of 
our results is limited to individuals who had stabilised 
from a FEM with psychotic features, representing the 
more severe end of the bipolar spectrum. The findings of 
this study are also not generalisable to people following 
stabilisation from first episode mania on other medica-
tions. Additionally, this study did not exclude FEM par-
ticipants with comorbidities such as substance abuse 
disorders, which may have impacted the findings. Also, 
due to the cross-sectional nature of this study, it is not 
possible to assess whether cognitive deficits existed prior 
to FEM.
Conclusions
Our findings revealed lower global intelligence in people 
following FEM may be evident prior to the onset of FEM, 
as well as specific cognitive deficits in processing speed, 
verbal learning and memory, working memory, and cog-
nitive flexibility. These findings highlight the necessity of 
cognitive testing early in the course of the disorder. Amid 
the clinically relevant findings of this study, the differ-
ences observed in verbal learning and memory compared 
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to non-verbal learning and memory may inform tailored 
interventions to address potential difficulties in func-
tioning in people with FEM. Future research on the tra-
jectory of cognitive functioning following FEM and the 
associated effects of treatment medications over time is 
warranted.
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